ANI Pharma releases corporate presentation outlining rare-disease shift, 2026 revenue outlook $1.1-$1.14 billion

ANI Pharmaceuticals

ANI Pharmaceuticals

ANIP

0.00
  • ANI Pharmaceuticals outlined 2026 guidance calling for total net revenue of $1,080-$1,140 million, adjusted non-GAAP EBITDA of $285-$300 million, adjusted non-GAAP diluted EPS of $9.19-$9.69.
  • Rare Disease positioned as primary growth driver, targeted at about 60% of total revenue, with Cortrophin Gel net revenue guided at $540-$575 million.
  • ILUVIEN net revenue forecast at $78-$83 million, with focus on returning the product to growth through commercial execution and patient access initiatives.
  • Board authorized a new $100 million share repurchase program.
  • Generics strategy centered on sustaining cash generation with a stated cadence of 10-15 launches annually.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.